296 related articles for article (PubMed ID: 18505077)
1. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated accelerated radiochemotherapy with cytoprotection (Chemo-HypoARC) for inoperable non-small cell lung carcinoma.
Koukourakis MI; Patlakas G; Froudarakis ME; Kyrgias G; Skarlatos J; Abatzoglou I; Bougioukas G; Bouros D
Anticancer Res; 2007; 27(5B):3625-31. PubMed ID: 17972527
[TBL] [Abstract][Full Text] [Related]
3. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
[TBL] [Abstract][Full Text] [Related]
4. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer.
Hirose T; Mizutani Y; Ohmori T; Ishida H; Hosaka T; Ando K; Shirai T; Okuda K; Ohnishi T; Horichi N; Kubota H; Adachi M
Cancer Chemother Pharmacol; 2006 Sep; 58(3):361-7. PubMed ID: 16331494
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of hyperfractionated accelerated radiotherapy (HART) after induction cisplatin (CDDP) and vinorelbine (VNR) for stage III non-small-cell lung cancer (NSCLC).
Ishikura S; Ohe Y; Nihei K; Kubota K; Kakinuma R; Ohmatsu H; Goto K; Niho S; Nishiwaki Y; Ogino T
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1117-22. PubMed ID: 15752891
[TBL] [Abstract][Full Text] [Related]
6. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer.
Koukourakis MI; Tsolos C; Touloupidis S
Urology; 2007 Feb; 69(2):245-50. PubMed ID: 17320657
[TBL] [Abstract][Full Text] [Related]
7. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
[TBL] [Abstract][Full Text] [Related]
8. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
Marks LB; Garst J; Socinski MA; Sibley G; Blackstock AW; Herndon JE; Zhou S; Shafman T; Tisch A; Clough R; Yu X; Turrisi A; Anscher M; Crawford J; Rosenman J;
J Clin Oncol; 2004 Nov; 22(21):4329-40. PubMed ID: 15514374
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study.
Fournel P; Robinet G; Thomas P; Souquet PJ; Léna H; Vergnenégre A; Delhoume JY; Le Treut J; Silvani JA; Dansin E; Bozonnat MC; Daurés JP; Mornex F; Pérol M;
J Clin Oncol; 2005 Sep; 23(25):5910-7. PubMed ID: 16087956
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
[TBL] [Abstract][Full Text] [Related]
14. Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study.
Vokes EE; Haraf DJ; Masters GA; Hoffman PC; Drinkard LC; Ferguson M; Olak J; Watson S; Golomb HM
Semin Oncol; 1996 Apr; 23(2 Suppl 5):48-52. PubMed ID: 8610237
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer.
Giorgio CG; Pappalardo A; Russo A; Santini D; Di Rosa C; Di Salvo C; Castorina S; Marletta F; Bellissima G; Palermo N; Scuderi C; Bordonaro R
Anticancer Drugs; 2007 Jul; 18(6):713-9. PubMed ID: 17762402
[TBL] [Abstract][Full Text] [Related]
16. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
Koukourakis MI; Yannakakis D
Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated accelerated radiotherapy, cytoprotection and capecitabine in the treatment of rectal cancer: a feasibility study.
Koukourakis MI; Simopoulos C; Pitiakoudis M; Lyratzopoulos N; Romanidis K; Giatromanolaki A; Polychronidis A; Kouklakis G; Sivridis E; Minopoulos G; Manolas K
Anticancer Res; 2008; 28(5B):3035-40. PubMed ID: 19031952
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of high-dose three-dimensional radiation therapy in the treatment of localised non-small-cell lung cancer.
Bellière A; Girard N; Chapet O; Khodri M; Kubas A; Souquet PJ; Mornex F
Cancer Radiother; 2009 Jul; 13(4):298-304. PubMed ID: 19525134
[TBL] [Abstract][Full Text] [Related]
19. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
20. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
Thongprasert S; Chewaskulyong B
J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
